Soonho Kwon1, Kathie L Hermayer2, Kathie Hermayer2. 1. Division of Endocrinology, Diabetes, and Medical Genetics, Department of Internal Medicine, Medical University of South Carolina, Charleston, South Carolina.. Electronic address: kwonso@musc.edu. 2. Division of Endocrinology, Diabetes, and Medical Genetics, Department of Internal Medicine, Medical University of South Carolina, Charleston, South Carolina.
Abstract
OBJECTIVES: Provide treatment guidelines for glucocorticoid-induced hyperglycemia and to understand the clinical implications of glucocorticoid-induced hyperglycemia. METHODS: The authors analyzed an electronic search (Medline) and a literature review of the pertinent articles published from 1980 to September 2012. RESULTS: In patients treated with glucocorticoids, the odds ratio for development of new-onset diabetes mellitus has been reported to be 1.36 to 2.31. The prevalence of abnormal glucose metabolism in post renal transplant patients taking glucocorticoids has been reported to be 17% to 32%. Sustained glucocorticoid treatment increases the potential for future cardiovascular disease through multiple pathways, resulting in a trade-off between benefit and harm. Complications related to glucocorticoid treatments are associated with the total glucocorticoid dose and duration of therapy. Other risk factors include age and body mass index. Understanding the pharmacodynamics and clinical implications of glucocorticoid-induced hyperglycemia can promote recognition and improvement of its treatment. CONCLUSIONS: Glucocorticoid-induced hyperglycemia has significant clinical implications in patients with diabetes mellitus and without diabetes mellitus. Early recognition and proper proactive management of glucocorticoid-induced hyperglycemia should enhance care for patients receiving glucocorticoid treatment. Furthermore, treatment has been effective for both the inpatient and the outpatient settings.
OBJECTIVES: Provide treatment guidelines for glucocorticoid-induced hyperglycemia and to understand the clinical implications of glucocorticoid-induced hyperglycemia. METHODS: The authors analyzed an electronic search (Medline) and a literature review of the pertinent articles published from 1980 to September 2012. RESULTS: In patients treated with glucocorticoids, the odds ratio for development of new-onset diabetes mellitus has been reported to be 1.36 to 2.31. The prevalence of abnormal glucose metabolism in post renal transplantpatients taking glucocorticoids has been reported to be 17% to 32%. Sustained glucocorticoid treatment increases the potential for future cardiovascular disease through multiple pathways, resulting in a trade-off between benefit and harm. Complications related to glucocorticoid treatments are associated with the total glucocorticoid dose and duration of therapy. Other risk factors include age and body mass index. Understanding the pharmacodynamics and clinical implications of glucocorticoid-induced hyperglycemia can promote recognition and improvement of its treatment. CONCLUSIONS: Glucocorticoid-induced hyperglycemia has significant clinical implications in patients with diabetes mellitus and without diabetes mellitus. Early recognition and proper proactive management of glucocorticoid-induced hyperglycemia should enhance care for patients receiving glucocorticoid treatment. Furthermore, treatment has been effective for both the inpatient and the outpatient settings.
Authors: Susan J Burke; Heidi M Batdorf; Adrianna E Eder; Michael D Karlstad; David H Burk; Robert C Noland; Z Elizabeth Floyd; J Jason Collier Journal: Am J Pathol Date: 2017-01-04 Impact factor: 4.307
Authors: Zanetta S Lamar; Andrew Dothard; LeAnne Kennedy; Scott Isom; Mac Robinson; Rakhee Vaidya; David Hurd; Donald McClain; Glenn Lesser Journal: Leuk Lymphoma Date: 2017-12-18
Authors: Scott L Weiss; Mark J Peters; Waleed Alhazzani; Michael S D Agus; Heidi R Flori; David P Inwald; Simon Nadel; Luregn J Schlapbach; Robert C Tasker; Andrew C Argent; Joe Brierley; Joseph Carcillo; Enitan D Carrol; Christopher L Carroll; Ira M Cheifetz; Karen Choong; Jeffry J Cies; Andrea T Cruz; Daniele De Luca; Akash Deep; Saul N Faust; Claudio Flauzino De Oliveira; Mark W Hall; Paul Ishimine; Etienne Javouhey; Koen F M Joosten; Poonam Joshi; Oliver Karam; Martin C J Kneyber; Joris Lemson; Graeme MacLaren; Nilesh M Mehta; Morten Hylander Møller; Christopher J L Newth; Trung C Nguyen; Akira Nishisaki; Mark E Nunnally; Margaret M Parker; Raina M Paul; Adrienne G Randolph; Suchitra Ranjit; Lewis H Romer; Halden F Scott; Lyvonne N Tume; Judy T Verger; Eric A Williams; Joshua Wolf; Hector R Wong; Jerry J Zimmerman; Niranjan Kissoon; Pierre Tissieres Journal: Intensive Care Med Date: 2020-02 Impact factor: 17.440
Authors: Ka-Eun Yoo; Rae Young Kang; Ju-Yeun Lee; Yu Jeung Lee; Sung Yun Suh; Kwi Suk Kim; Hyang Sook Kim; Se-Hoon Lee; Byung Koo Lee Journal: Support Care Cancer Date: 2014-12-13 Impact factor: 3.603
Authors: Henrik Oster; Etienne Challet; Volker Ott; Emanuela Arvat; E Ronald de Kloet; Derk-Jan Dijk; Stafford Lightman; Alexandros Vgontzas; Eve Van Cauter Journal: Endocr Rev Date: 2017-02-01 Impact factor: 19.871